MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Biocon to launch most awaited DCGI approved COVID-19 drug Itolizumab; stock jumps five percent

Biocon to launch most awaited DCGI approved COVID-19 drug Itolizumab; stock jumps five percent

Biocon's shares have seen a rapid rise. The stock value has increased to almost five percent on July 14, after the firm announced that it would be launching the most anticipated and awaited biologic drug Itolizumab for the treatment of COVID-19 patients. The drug is priced at Rs. 8000 per vial. Biocon has received approval from the Drugs Controller General of India (DCGI) to market the injection, a 25mg/mL solution for immediate and emergency use in India.

"Itolizumab's unique mechanism of action made it an ideal candidate for treating the 'cytokine storm,' which is a leading cause of death in COVID-19 patients. I am pleased that our R&D and clinical teams delivered on this promising hypothesis in such a short period. It is a proud moment for all of us at Biocon. We want more and more patients to benefit from this therapy," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

The drug will help treat cytokine release syndrome, especially in patients with moderate to acute respiratory distress syndrome (ARDS) due to COVID-19. The drug will be manufactured as an intravenous injection at the bio-manufacturing facility of Biocon Park, Bengaluru. The drug has been approved based on successful and randomized clinical trials at multiple hospitals in Mumbai and New Delhi. The drug also has achieved secondary endpoints and biomarkers, the company said.

YOU MAY ALSO LIKE

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...

RECOMMENDED